These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1769469)

  • 1. [Effects of biliary lithogenesis in acromegalic patients with long-term octreotide (SMS 201-995) treatment].
    Buscail LE; Puel-Bousquet C; Harris AG; Tauber JP; Escourrou JR; Delvaux MM; Vaysse NM; Bayard F; Ribet A
    Gastroenterol Clin Biol; 1991; 15(11):800-4. PubMed ID: 1769469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients.
    Tauber JP; Poncet MF; Harris AG; Barthel HR; Simonetta-Chateauneuf C; Buscail L; Bayard F
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3262-6. PubMed ID: 7593435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholelithiasis and acromegaly: therapeutic strategies.
    Montini M; Gianola D; Pagani MD; Pedroncelli A; Caldara R; Gherardi F; Bonelli M; Lancranjan I; Pagani G
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):401-6. PubMed ID: 8187305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.
    Hussaini SH; Pereira SP; Murphy GM; Kennedy C; Wass JA; Besser GM; Dowling RH
    Gut; 1995 Jan; 36(1):126-32. PubMed ID: 7890216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.
    Shi YF; Zhu XF; Harris AG; Zhang JX; Dai Q
    J Clin Endocrinol Metab; 1993 Jan; 76(1):32-7. PubMed ID: 8421099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gallstones during octreotide therapy.
    Dowling RH; Hussaini SH; Murphy GM; Besser GM; Wass JA
    Metabolism; 1992 Sep; 41(9 Suppl 2):22-33. PubMed ID: 1355588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of bile composition and physical chemistry in the pathogenesis of octreotide-associated gallbladder stones.
    Hussaini SH; Murphy GM; Kennedy C; Besser GM; Wass JA; Dowling RH
    Gastroenterology; 1994 Nov; 107(5):1503-13. PubMed ID: 7926514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
    Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly. A prospective study.
    Erlinger S; Chanson P; Dumont M; Ponsot P; Warnet A; Harris AG
    Dig Dis Sci; 1994 Nov; 39(11):2384-8. PubMed ID: 7956607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prospective study of functional changes in the gallbladder and formation of gallstones induced by long-term treatment of somatostatin analogue SMS201-995 in patients of active acromegaly].
    Zhu XF; Shi YF; Zhang JX
    Zhonghua Nei Ke Za Zhi; 1991 Jul; 30(7):405-8, 455. PubMed ID: 1752152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones.
    Hussaini SH; Pereira SP; Veysey MJ; Kennedy C; Jenkins P; Murphy GM; Wass JA; Dowling RH
    Gut; 1996 May; 38(5):775-83. PubMed ID: 8707128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective examination of octreotide-induced gall-bladder changes in acromegaly.
    Eastman RC; Arakaki RF; Shawker T; Schock R; Roach P; Comi RJ; Gorden P
    Clin Endocrinol (Oxf); 1992 Mar; 36(3):265-9. PubMed ID: 1563079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of gall bladder dynamics, cholecystokinin release and the development of gallstones during octreotide therapy for acromegaly.
    Ewins DL; Javaid A; Coskeran PB; Shah S; Butler J; Deprez PH; Miell J; Calam J; Barrett JJ; Dawson JM
    Q J Med; 1992 Apr; 83(300):295-306. PubMed ID: 1631261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management.
    Redfern JS; Fortuner WJ
    Am J Gastroenterol; 1995 Jul; 90(7):1042-52. PubMed ID: 7611194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of gallbladder contractility after withdrawal of long-term octreotide therapy in acromegalic patients.
    Shi YF; Zhu XF; Harris AG; Zhang JX; Deng JY
    Acta Endocrinol (Copenh); 1993 Sep; 129(3):207-12. PubMed ID: 8212985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide.
    Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF
    Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly.
    Plöckinger U; Dienemann D; Quabbe HJ
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1658-62. PubMed ID: 2229321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final outcome of ursodeoxycholic acid treatment in 126 patients with radiolucent gallstones.
    Gleeson D; Ruppin DC; Saunders A; Murphy GM; Dowling RH
    Q J Med; 1990 Jul; 76(279):711-29. PubMed ID: 2217675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.